Business
CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®
Tuesday, May 19th @ 12pm Eastern Time BERKELEY HEIGHTS, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical
About this update from Cormedix Inc.
[{"type":"text","content":"Tuesday, May 19th @ 12pm Eastern Time\nBERKELEY HEIGHTS, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, will host a call with Key Opinion Leaders (KOLs) on the potential of Neutrolin® for addressing antimicrobial resistance and catheter-related bloodstream infections (CRBSIs) on Tuesday, May 19th at 12pm Eastern Time.\n The call will feature presentations by KOLs Bruce Polsky, MD, MACP, FIDUSA (NYU Long Island School of Medicine and NYU Winthrop Hospital), Bruce Reidenberg, MD, FAAP, FCP (Weill Cornell Medicine), and Nelson P. Kopyt, DO (Lehigh Valley Health Network) who will discuss antimicrobial resistance, the current CRBSI landscape in patients with hemodialysis catheters, and Neutrolin®'s potential for preventing CRBSIs in these patients. Drs Polsky, Reidenberg, and Kopyt will be available to answer questions at the conclusion of the call. Neutrolin® is a novel non-antibiotic antimicrobial solution being developed for the prevention of catheter-related bloodstream infections (“CRBSIs”) in patients with end-stage renal disease receiving hemodialysis through a central venous catheter. It has not yet been approved by FDA. The Company has begun NDA submission under rolling review with potential approval in hemodialysis in 2H20. Neutrolin® has FDA Fast Track status and is designated as a Qualified Infectious Disease Product (QIDP), which provides five years of market exclusivity added to the five years received for approval as a New Chemical Entity (NCE) for a total of 10 years of potential market exclusivity. Conference Call & Webcast InformationTuesday, May 19th @ 12pm Eastern TimeDomestic: 877-423-9813International: 201-689-8573Conference ID: 13703060Webcast: Click Here for Webcast Bruce Polsky, MD, MACP, FIDSA is Associate Dean, Faculty and Professor and Chairman of the Department of Medicine at NYU Long Island School of Medicine and NYU Winthrop Hospital in Mineola, LI, New York. Dr. Polsky was previously Chairman of the Department of Medicine (2009-2015), Medical Director of the Clinical Virology Laboratory (1998-2015) and Hospital Epidemiologist (1998-2015) at Mount Sinai St. Luke's and Mount Sinai Roosevelt Hospitals and Professor ...